Download PDF
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2013; 34(04): 327-329
DOI: 10.4103/0971-5851.125261
CASE REPORT

Acute promyelocytic leukemia relapsing into acute myeloid leukemia-M2 with normal cytogenetics

Ranjit Kumar Sahoo
Department of Medical Oncology, Dr. B. R. A. Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India
,
Lalit Kumar
Department of Medical Oncology, Dr. B. R. A. Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India
,
Rajive Kumar
Department of Medical Oncology, Dr. B. R. A. Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India
,
Atul Sharma
Department of Medical Oncology, Dr. B. R. A. Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India
› Author Affiliations
› Further Information
Also available at
  PDF Download Permissions and Reprints

Abstract

The use of all trans-retinoic acid (ATRA) and combination chemotherapy has made acute promyelocytic leukemia (APL) a potentially curable leukemia. Late sequelae of the treatment of APL have therefore become an important consideration in the overall treatment strategy. We report a patient with APL who achieved complete clinical and molecular remission after treatment with daunorubicin and ATRA. Three years later, she developed acute myeloid leukemia (AML), M2 subtype without any evidence of relapse of the APL clone. Karyotypic analysis showed a normal female karyotype.

Keywords

Acute promyelocytic leukemia - acute myeloid leukemia (AML) - secondary AML - therapy related AML


Publication History

Article published online:
19 July 2021

© 2013. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol 1976;33:451-8.
  • 2 Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Woods WG, et al. All-trans retinoic acid in acute promyelocytic leukemia: Long-term outcome and prognostic factor analysis from the North American Intergroup protocol. Blood 2002;100:4298-302
  • 3 De Botton S, Chevret S, Sanz M, Dombret H, Thomas X, Guerci A, et al. Additional chromosomal abnormalities in patients with acute promyelocytic leukaemia (APL) do not confer poor prognosis: Results of APL 93 trial. Br J Haematol 2000;111:801-6.
  • 4 Hernández JM, Martín G, Gutiérrez NC, Cervera J, Ferro MT, Calasanz MJ, et al. Additional cytogenetic changes do not influence the outcome of patients with newly diagnosed acute promyelocytic leukemia treated with an ATRA plus anthracyclin based protocol. A report of the Spanish group PETHEMA. Haematologica 2001;86:807-13.
  • 5 Batzios C, Hayes LA, He SZ, Quach H, McQuilten ZK, Wall M, et al. Secondary clonal cytogenetic abnormalities following successful treatment of acute promyelocytic leukemia. Am J Hematol 2009;84:715-9.
  • 6 Latagliata R, Petti MC, Fenu S, Mancini M, Spiriti MA, Breccia M, et al. Therapy-related myelodysplastic syndrome-acute myelogenous leukemia in patients treated for acute promyelocytic leukemia: An emerging problem. Blood 2002;99:822-4.
  • 7 Lobe I, Rigal-Huguet F, Vekhoff A, Desablens B, Bordessoule D, Mounier C, et al. Myelodysplastic syndrome after acute promyelocytic leukemia: The European APL group experience. Leukemia 2003;17:1600-4.
  • 8 Zompi S, Viguié F. Therapy-related acute myeloid leukemia and myelodysplasia after successful treatment of acute promyelocytic leukemia. Leuk Lymphoma 2002;43:275-80.
  • 9 Jubashi T, Nagai K, Miyazaki Y, Nakamura H, Matsuo T, Kuriyama K, et al. A unique case of t(15;17) acute promyelocytic leukaemia (M3) developing into acute myeloblastic leukaemia (M1) with t(7;21) at relapse. Br J Haematol 1993;83:665-8.
  • 10 Desangles F, Vilain E, Arborio M, De Revel T, Flandrin G. t(15;17) hypergranular acute promyelocytic leukemia (M3) developing into a t(3;6) M3 without t(15;17) at relapse. Leuk Lymphoma 1995;19:185-8.
  • 11 Hatzis T, Standen GR, Howell RT, Savill C, Wagstaff M, Scott GL. Acute promyelocytic leukaemia (M3): Relapse with acute myeloblastic leukaemia (M2) and dic(5;17) (q11;p11). Am J Hematol 1995;48:40-4.
  • 12 Charrin C, Ritouet D, Campos L, Devaux Y, Archimbaud E, Fraisse J, et al. Association of t(15;17) and t(8;21) in the initial phase of an acute promyelocytic leukemia. Cancer Genet Cytogenet 1992;58:177-80.
  • 13 Bonomi R, Giordano H, del Pilar Moreno M, Bodega E, Landoni AI, Gallagher R, et al. Simultaneous PML/RARalpha and AML1/ETO expression with t(15;17) at onset and relapse with only t(8;21) in an acute promyelocytic leukemia patient. Cancer Genet Cytogenet 2000;123:41-3.
  • 14 Purizaca J., I. Meza, and R. Pelayo, Early Lymphoid Development and Microenvironmental Cues in B-cell Acute Lymphoblastic Leukemia. Arch Med Res, 2012.